HA
RPRX icon

Homestead Advisers’s Royalty Pharma RPRX Stock Holding History

Homestead Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.9M Buy
1,657,242
+4,200
+0.3% +$219K 2.31% 15
2026
Q1 		$78.9M Sell
1,653,042
-18,500
-1% -$810K 2.12% 19
2025
Q4 		$64.6M Sell
1,671,542
-230,898
-12% -$8.8M 1.71% 27
2025
Q3 		$67.1M Sell
1,902,440
-37,000
-2% -$1.34M 1.6% 29
2025
Q2 		$69.9M Buy
1,939,440
+8,300
+0.4% +$275K 1.66% 29
2025
Q1 		$60.1M Hold
1,931,140
– – 1.47% 35
2024
Q4 		$49.3M Buy
1,931,140
+73,000
+4% +$1.94M 1.19% 41
2024
Q3 		$52.6M Sell
1,858,140
-1,800
-0.1% -$49.9K 1.25% 40
2024
Q2 		$49M Sell
1,859,940
-32,600
-2% -$904K 1.21% 39
2024
Q1 		$57.5M Buy
1,892,540
+547,000
+41% +$16.1M 1.35% 35
2023
Q4 		$37.8M Buy
1,345,540
+2,500
+0.2% +$68.7K 0.97% 42
2023
Q3 		$36.5M Buy
1,343,040
+21,000
+2% +$624K 1.01% 41
2023
Q2 		$40.6M Buy
1,322,040
+6,700
+0.5% +$227K 1.08% 37
2023
Q1 		$47.4M Sell
1,315,340
-28,400
-2% -$1.05M 1.32% 34
2022
Q4 		$53.1M Buy
1,343,740
+400
+0% +$16.7K 1.42% 34
2022
Q3 		$54M Sell
1,343,340
-3,200
-0.2% -$137K 1.63% 30
2022
Q2 		$56.6M Hold
1,346,540
– – 1.6% 28
2022
Q1 		$52.5M Sell
1,346,540
-21,000
-2% -$825K 1.28% 35
2021
Q4 		$54.5M Buy
1,367,540
+209,700
+18% +$8.15M 1.25% 35
2021
Q3 		$41.8M Buy
1,157,840
+437,600
+61% +$17M 1.02% 43
2021
Q2 		$29.5M Buy
+720,240
New +$30.6M 0.68% 50

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Homestead Advisers's RPRX Position: Q2 2026 in Review

Homestead Advisers increased its Royalty Pharma (RPRX) stake by 0.25% in Q2 2026, buying an estimated $219K and bringing the position to 1,657,242 shares worth $92.9M. The position accounts for 2.31% of the portfolio, ranked #15.

Homestead Advisers first reported a position in RPRX in Q2 2021 and has held it in 21 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Homestead Advisers held 1,657,242 shares of Royalty Pharma worth $92.9M as of Q2 2026.
  • Homestead Advisers bought 4,200 Royalty Pharma shares in Q2 2026, an estimated $219K.
  • Royalty Pharma made up 2.31% of Homestead Advisers's portfolio in Q2 2026, its #15 holding.
  • Homestead Advisers first reported a position in Royalty Pharma in Q2 2021 and has held it in 21 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Homestead Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.